Axxam raises money from a corporate investor

Axxam, the Bayer spinoff with the aim to address the big pharma's increasing demand for truly innovative lead structures, by the full application of the “LeadEngine" approach, received 3,2 million euros as a grant and 1 million euros from a Corporate Investor.

Axaam participated to the 8th edition of the Intesa Sanpaolo Startup Initiative on Biotech and Healthcare in April 2011.

You can find here more information about the news: http://www.axxam.com/news/news.asp